Save 10% off on your first order with coupon code: PANDA10

Health & Wellness Blog

6Feb, 2026

Zepbound Side Effects: Nausea, GI Symptoms & Muscle Pain Timeline Guide

February 6, 2026|

Zepbound side effects impact approximately 82% of users during the first month of treatment, with nausea (up to 29%), diarrhea (up to 23%), constipation (up to 17%), and vomiting (up to 13%) being the most frequently reported according to FDA prescribing information. These gastrointestinal symptoms typically peak during weeks 4-8 when patients are titrating to [...]

6Feb, 2026

Mounjaro Nausea: 12-24% Rate Peaks Week 4 – 90% Resolve Management Guide

February 6, 2026|

Mounjaro (tirzepatide) is an FDA-approved medication that helps manage blood glucose levels in adults with Type 2 diabetes and is also highly effective for weight loss. While this weight loss injection has shown remarkable results in clinical trials, helping people lose weight significantly, nausea from Mounjaro remains the most common side effect that patients experience [...]

6Feb, 2026

Mounjaro Face: Facial Fat Loss from Rapid Weight Loss – Prevention Guide

February 6, 2026|

Mounjaro face describes the gaunt, hollow facial appearance that develops when tirzepatide therapy causes rapid facial fat loss. This phenomenon affects approximately 15-25% of women over 40 using weight loss medications and results from the body losing subcutaneous fat from the cheeks, temples, and under-eye areas faster than the skin can adapt. According to the [...]

6Feb, 2026

Does Mounjaro Make You Tired? 8-12% Fatigue Rate + Evidence-Based Recovery

February 6, 2026|

Mounjaro (tirzepatide) is an FDA-approved medication to treat type 2 diabetes and support weight loss by mimicking two naturally occurring hormones: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. These hormones work by enhancing insulin secretion, reducing appetite, slowing gastric emptying, and managing blood sugar levels. While taking Mounjaro, many patients report feeling tired-particularly during the initial [...]

6Feb, 2026

Zepbound vs Wegovy: 20% vs 14% Weight Loss – Head-to-Head Trial

February 6, 2026|

Zepbound beats Wegovy with 20.2% vs 13.7% body weight loss in the first-ever head-to-head trial (SURMOUNT-5), published in the New England Journal of Medicine. The key difference: Zepbound is a dual GLP-1 and GIP receptor agonist, while Wegovy targets only GLP-1. Both are FDA-approved injectable weight loss medications that require weekly injections alongside healthy eating [...]

6Feb, 2026

How Much Weight Can You Lose on Wegovy? 15-17% Average + Timeline Chart

February 6, 2026|

The average weight loss on Wegovy is 15% of body weight (approximately 35 pounds) after 68 weeks of treatment with the 2.4mg maintenance dose, according to clinical trial data published in the New England Journal of Medicine. This once-weekly injection, containing the active ingredient semaglutide, works by mimicking a natural hormone called GLP-1 that signals [...]

20Feb, 2026

Trulicity Coupon 2026: $25 Savings Card, Copay, Discounts Guide

February 20, 2026|

As of early 2026, the average retail price of Trulicity without insurance is approximately $1,395.75 for four Trulicity pens a standard 30-day supply. The good news: several savings programs exist to help eligible patients dramatically reduce what they pay out [...]

17Feb, 2026

Zepbound Insurance Coverage: Complete Guide to Prior Authorization & Approval

February 17, 2026|

Zepbound insurance coverage stands at approximately 45% for commercial plans requiring BMI ≥30 or ≥27 with comorbidities, while Medicare excludes weight-loss indications entirely. Employer-sponsored plans show 55% approval rates after prior authorization. Roughly 97 million Americans are in plans that [...]

13Feb, 2026

Mounjaro Dosage: Complete 2.5mg→15mg Titration Chart + Missed Dose Protocol

February 13, 2026|

Mounjaro (tirzepatide) is an FDA-approved once-weekly injectable medicine manufactured by Eli Lilly for adults and children aged 10 years and older with type 2 diabetes. The active ingredient tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) [...]

6Feb, 2026

Does Mounjaro Make You Tired? 8-12% Fatigue Rate + Evidence-Based Recovery

February 6, 2026|

Mounjaro (tirzepatide) is an FDA-approved medication to treat type 2 diabetes and support weight loss by mimicking two naturally occurring hormones: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. These hormones work by enhancing insulin secretion, reducing appetite, slowing gastric emptying, and [...]

5Feb, 2026

Trulicity vs Wegovy: Wegovy 15% Weight Loss vs Trulicity 7 lbs – Diabetes vs Obesity Drugs

February 5, 2026|

Wegovy delivers approximately 15% body weight loss in clinical trials-dramatically outperforming Trulicity’s average weight reduction of about 7–10 lbs (3–5% of body weight). Both are GLP-1 receptor agonists administered as once-weekly injections, yet Wegovy produces roughly 2.5 times greater weight [...]

1Sep, 2025

Ozempic vs Insulin

September 1, 2025|

Effective blood glucose management is a critical need for many. Ozempic and insulin are two commonly used diabetes medications. While both address diabetes, they function differently. Ozempic is a prescription medication for adults with type 2 diabetes. Interestingly, it also [...]

4Aug, 2025

Is Compounded Mounjaro Safe? Understanding Tirzepatide Compounding for Informed Choices

August 4, 2025|

Tirzepatide is a prescription drug that has been gaining popularity. Millions are exploring it for weight management and diabetes. But sometimes, the exact medication isn't readily available. This leads to "compounding."  What are Compounded Drugs? Compounded versions of medications are [...]

3Jun, 2025

Does Ozempic Cause Hair Loss?

June 3, 2025|

You've scrolled through social media, seen the news, and maybe even heard friends talking about Ozempic and its remarkable weight loss results. It's become a household name, but with its growing popularity comes a wave of questions, especially regarding potential [...]

Go to Top
X